Capricor Therapeutics Inc. ($capr) has been actively responding to a recent FDA advisory committee vote that rejected its initial application to treat cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. Following the 3-9 vote against the cardiomyopathy indication, the company is pivoting to focus on a narrower regulatory path targeting upper limb skeletal muscle function, which aligns with the primary endpoint of its HOPE-3 clinical trial. This shift involves submitting an amended Biologics License Application (BLA) incorporating 24-month open-label extension data, a move the FDA has agreed to review, extending the original August 22 PDUFA deadline. The HOPE-3 trial’s upper limb results showed a statistically significant slowing of disease progression, providing a stronger foundation for this revised indication.
Despite this regulatory challenge, Capricor’s management remains committed to advancing deramiocel, emphasizing that the primary skeletal muscle endpoint remains statistically and clinically significant despite some revisions to secondary cardiac data. The company’s San Diego manufacturing facility is operational and ready to support a potential launch, though commercial activities are being paced cautiously pending regulatory clarity. Financially, Capricor reported a widening net loss in Q2 2026, with cash reserves declining to $237.9 million, reflecting increased R&D and administrative expenses. Meanwhile, pipeline projects outside deramiocel are on hold, and ongoing arbitration with NS Pharma adds complexity to the company’s near-term outlook. Investors have seen volatility in $capr shares amid these developments, reflecting the high stakes of the FDA review and the company’s strategic recalibration.
Markets will resume tomorrow morning at 9:30 AM ET.
Did you know?
Stocks with clear regulatory pathways often experience significant price swings around FDA decisions, as these rulings can make or break the commercial viability of biotech therapies.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments